Results 171 to 180 of about 5,082,017 (204)

[Hirudin therapy and blood coagulability].

Kardiologiia, 1992
The changes in blood coagulative properties, which occur in the treatment with medical leeches, were studied in 57 patients with coronary heart, rheumatic and chronic pulmonary diseases. Hirudin therapy was established to affect blood coagulation. The leech salina penetrated into the skin wound to block hemostasis. Having entered the circulating blood,
G S, Isakhanian, K S, Tumasian, Z E, Barsegian, L S, Mkrtchian, A K, Karapetian, N G, Fldzhian   +5 more
openaire   +1 more source

Hirudin: Pharmakologie und Therapie

1999
Der medizinische Blutegel (Hirudo medicinalis), ein blutsaugender Parasit, eroffnet durch einen Y-formigen Bis der 3 bezahnten Kiefer Blutgefase in der Unterhautregion seiner Opfer. Durch die Benetzung der Wundrander mit dem Sekret der kranialen Speicheldrusen des Blutegels wird die Wunde offengehalten und gleichzeitig das gesaugte Blut antikoaguliert.
openaire   +1 more source

Engineered Microrobots for Targeted Delivery of Bacterial Outer Membrane Vesicles (OMV) in Thrombus Therapy.

Small
In the realm of thrombosis treatment, bioengineered outer membrane vesicles (OMVs) offer a novel and promising approach, as they have rich content of bacterial-derived components.
Z. Cong, Yangyang Li, Leiming Xie, Qiwei Chen, Menghuan Tang, Phonpilas Thongpon, Yanxiao Jiao, Song Wu   +7 more
semanticscholar   +1 more source

Leech Therapy: An Old Method Applied in Modern Medicine

International Journal of Innovations in Science, Engineering And Management
Leech therapy, also known as hirudotherapy, originated in ancient medicine when people used leeches for therapeutic purposes. Different cultures around the world have found these blood-draining, wormlike creatures since antiquity.
Malsoor Thirumala, K. Vanaja
semanticscholar   +1 more source

[Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin].

Presse medicale (Paris, France : 1983), 1996
Heparin-induced thrombocytopenia is an uncommon and severe complication of heparin therapy. Both venous and arterial thromboembolic events can occur, requiring withdrawal of the heparin therapy. When anticoagulant therapy is mandatory, recombinant hirudin can be used.We used recombinant hirudin (HBW 023) in 6 patients with heparin induced ...
F, Schiele, A, Vuillemenot, T, Mouhat, Y, Kieffer, T, Anguenot, Y, Bernard, J P, Bassand   +6 more
openaire   +1 more source

[Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers].

Herz, 1999
Plaque rupture with consecutive formation of an intraluminal, platelet-rich thrombus is the central mechanism leading to critical reduction of coronary perfusion in the acute coronary syndrome. Current therapeutic strategies aim at the inhibition of activation of platelets and the coagulation cascade and the suppression of platelet aggregation and ...
A, Gaede, W, Terres
openaire   +1 more source

Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.

The American journal of cardiology, 1995
This retrospective analysis reviewed 183 patients with acute myocardial infarction who were given front-loaded recombinant tissue-type plasminogen activator (rt-PA) and r-hirudin (HBW 023) in 1 of 4 dose groups (bolus dose of 0.07, 0.1, 0.2, or 0.4 mg/kg, followed by an infusion of 0.05, 0.06, 0.1, or 0.15 mg/kg/hour over 48 hours).
U, Zeymer, R, von Essen, U, Tebbe, W, Niederer, W, Mäurer, A, Vogt, K L, Neuhaus   +6 more
openaire   +1 more source

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Ca-A Cancer Journal for Clinicians, 2022
William A Hal, X Allen Li, Christopher Schultz   +2 more
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski   +2 more
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly